I haven't updated my bio for awhile but I am still hormone sensitive MPCA. My PSA last month was undetectable. I had a bilateral orchiectomy in February but was also on Erleada which I stayed on until recently.
So what's changed is that I also have Stage I Multiple Myeloma. Erleada and Xandti are both Contraindicated with my MM protocol.
I won't see my One again until November but am working with his PA who spoke to him about ADT.
He wants my to take NUBEQA® (darolutamide) - His first preference.
Otherwise ZYTIGA® (abiraterone acetate) - his less preferred. I looked at side effects of both and see little to no difference other that abiraterone lists Infected nose, sinuses, or throat (cold) as a common side effect. Infections are obviously dangerous when the MM treatment goal is to wipe clean your white cells.
MM, for those that don't know has my white blood cells overtaking my marrow, then eventually bone tissue, and the treatment involve wiping out the cells using Revlimid and Brotezomib. Also, Dexamethazone is used as part of the 4 month long induction therapy, with the goal to put my in remission. That's followed by a stem cell transplant but that's for another time
Question, and I will ask this of the PA on Monday, why would the oncologist prefer daralutamide over abiraterone? Or differently stated, can someone any of you weigh in on the differences?
Greatly appreciated as always.